MedTrace Logo

Therapeutic Efficacy Study of Pyrimethamine/Sulfdoxine (Fansidar®) for the Treatment of Uncomplicated Falciparum Malaria in the Peruvian Amazon

NCT00951106 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2010-07-27

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy of pyrimethamine/sulfdoxine (Fansidar®) for the treatment of uncomplicated falciparum malaria in the Peruvian Amazon. Reports in the mid 1990s indicated that Fansidar was failing to cure patients with confirmed falciparum malaria. The study design was based on accepted WHO parasitological and clinical outcomes to determine the overall efficacy of Fansider and inform the Peruvian National Malaria Control authorities as to the continued wisdom of recommending Fansidar as first line treatment for uncomplicated falciparum malaria in the Peruvian Amazon.

Conditions

  • Malaria, Vivax
  • Malaria, Falciparum

Interventions

DRUG

Pyrimethamine/sulfdoxine (Fansidar)

Sponsors & Collaborators

  • Walter Reed Army Institute of Research (WRAIR)

    lead FED

Principal Investigators

  • Alan Magill, MD · Walter Reed Army Institute of Research (WRAIR)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-01-31
Primary Completion
1999-06-30
Completion
2009-08-31

Countries

  • Peru

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00951106 on ClinicalTrials.gov